Immunotherapy of distant metastatic disease

D. Schadendorf*, S. M. Algarra, L. Bastholt, G. Cinat, B. Dreno, A. M.M. Eggermont, E. Espinosa, J. Guo, A. Hauschild, T. Petrella, J. Schachter, P. Hersey

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Immunotherapy of metastatic melanoma consists of various approaches leading to specific or non-specific immunomodulation. The use of FDA-approved interleukin (IL)-2 alone, in combination with interferon α, and/orwithvarious chemotherapeutic agents (biochemotherapy) is associated with significant toxicity and poor efficacy that does not improve overall survival of 96% of patients. Many studies with allogeneic and autologous vaccines have demonstrated no clinical benefit, and some randomised trials even showed a detrimental effect in the vaccine arm. The ongoing effort to develop melanoma vaccines based on dendritic cells and peptides is driven by advances in understanding antigen presentation and processing, and by new techniques of vaccine preparation, stabilisation and delivery. Several agents that have shown promising activity in metastatic melanoma including IL-21 and monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) or CD137 are discussed. Recent advances of intratumour gene transfer technologies and adoptive immunotherapy, which represents a promising although technically challenging direction, are also discussed.

Original languageEnglish
Pages (from-to)vi41-vi50
JournalAnnals of Oncology
Issue numberSUPPL. 4
StatePublished - 2009
Externally publishedYes


FundersFunder number
Schering Plough
Schering-Plough/Essex Pharma
Synta Pharmaceuticals
Bristol-Myers Squibb


    • Adoptive immunotherapy
    • Anti-CTLA-4
    • Interferon
    • Interleukin
    • Metastatic melanoma
    • Vaccine


    Dive into the research topics of 'Immunotherapy of distant metastatic disease'. Together they form a unique fingerprint.

    Cite this